New developments for antibody-drug conjugate-based therapeutic approaches

被引：194

作者：

de Goeij, Bart E. C. G. ^{[1
]}

Lambert, John M. ^{[2
]}

机构：

[1] Genmab, Yalelaan 60, NL-3584 CM Utrecht, Netherlands

[2] ImmunoGen Inc, 830 Winter St, Waltham, MA 02451 USA

来源：

CURRENT OPINION IN IMMUNOLOGY | 2016年 / 40卷

关键词：

PHASE-I; PATIENTS PTS; ANTITUMOR-ACTIVITY; CLINICAL ACTIVITY; DOSE-ESCALATION; CELL CARCINOMA; IMMUNOCONJUGATE; ADC; EFFICACY; AGENTS;

D O I：

10.1016/j.coi.2016.02.008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The clinical success of Adcetris (R) (brentuximab vedotin) and Kadcyla (R) (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues. Despite the use of tumor-specific antibodies, the emerging clinical data with ADCs indicates that adverse effects frequently occur before ADCs have reached their optimal therapeutic dose, resulting in a relatively narrow therapeutic window. This review summarizes the therapeutic window of ADCs currently in clinical development, along with some strategies that may help to widen the window.

引用

页码：14 / 23

页数：10

共 67 条

[61] Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) [J].

Uppal, Hirdesh ;

Doudement, Estelle ;

Mahapatra, Kaushiki ;

Darbonne, Walter C. ;

Bumbaca, Daniela ;

Shen, Ben-Quan ;

Du, Xiaoyan ;

Saad, Ola ;

Bowles, Kristin ;

Olsen, Steve ;

Phillips, Gail D. Lewis ;

Hartley, Dylan ;

Sliwkowski, Mark X. ;

Girish, Sandhya ;

Dambach, Donna ;

Ramakrishnan, Vanitha .

CLINICAL CANCER RESEARCH, 2015, 21 (01) :123-133

[62] The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers [J].

van der Lee, Miranda M. C. ;

Groothuis, Patrick G. ;

Ubink, Ruud ;

van der Vleuten, Monique A. J. ;

van Achterberg, Tanja A. ;

Loosveld, Eline M. ;

Damming, Desiree ;

Jacobs, Danielle C. H. ;

Rouwette, Myrthe ;

Egging, David F. ;

van den Dobbelsteen, Diels ;

Beusker, Patrick H. ;

Goedings, Peter ;

Verheijden, Gijs F. M. ;

Lemmens, Jacques M. ;

Timmers, Marco ;

Dokter, Wim H. A. .

MOLECULAR CANCER THERAPEUTICS, 2015, 14 (03) :692-703

[63] Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma [J].

Younes, Anas ;

Kim, Stella ;

Romaguera, Jorge ;

Copeland, Amanda ;

Farial, Silvana de Castro ;

Kwak, Larry W. ;

Fayad, Luis ;

Hagemeister, Frederick ;

Fanale, Michelle ;

Neelapu, Sattva ;

Lambert, John M. ;

Morariu-Zamfir, Rodica ;

Payrard, Sandrine ;

Gordon, Leo I. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2776-2782

[64] Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. [J].

Younes, Anas ;

Bartlett, Nancy L. ;

Leonard, John P. ;

Kennedy, Dana A. ;

Lynch, Carmel M. ;

Sievers, Eric L. ;

Forero-Torres, Andres .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19) :1812-1821

[65]

Zambrano CC., 2014, J CLIN ONCOL, V32, P3546, DOI 10.1200/jco.2014.32.15_suppl.3546

[66] MLNO264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC), demonstrates antitumor activity alone and in combination with gemcitabine in human pancreatic cancer xenograft models expressing GCC. [J].

Zhang, Julie ;

Gallery, Melissa ;

Wyant, Tim ;

Stringer, Brad ;

Manfredi, Mark ;

Danaee, Hadl ;

Velby, Petter .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)

[67] Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance [J].

Zitvogel, Laurence ;

Galluzzi, Lorenzo ;

Smyth, Mark J. ;

Kroemer, Guido .

IMMUNITY, 2013, 39 (01) :74-88

← 1 2 3 4 5 6 7 →